Dashboard
Manage Tickers

ANTX AN2 Therapeutics, Inc.

Nasdaq an2therapeutics.com


$ 1.20 $ 0.02 (1.69 %)    

Tuesday, 11-Nov-2025 15:59:51 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 1.2
$ 1.18
$ 1.10 x 700
$ 1.27 x 460
$ 1.13 - $ 1.20
$ 0.98 - $ 1.68
106,852
na
32.79M
$ 1.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
AN2 Therapeutics Announces Collaboration A...
11/10/2025 12:11:37

AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advanc...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 21:07:00

an2-therapeutics-q2-eps-021-beats-030-estimate
AN2 Therapeutics Q2 EPS $(0.21) Beats $(0....
08/12/2025 20:20:45

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0....

an2-therapeutics-completes-dosing-in-first-single-ascending-dose-cohort-in-phase-1-trial-evaluating-an2-502998-for-chagas-disease
AN2 Therapeutics Completes Dosing In first...
08/12/2025 11:06:07

an2-therapeutics-and-dndi-collaborate-announce-collaboration-to-advance-development-of-an2-502998-in-chronic-chagas-disease
AN2 Therapeutics And DNDi Collaborate Anno...
07/23/2025 11:04:23

an2-therapeutics-completed-its-200-patient-observational-study-in-acute-melioidosis-the-study-evaluated-patients-receiving-the-current-standard-of-care-iv-meropenem-or-ceftazidime
AN2 Therapeutics Completed Its 200-patient...
06/30/2025 11:11:17

Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-co...

an2-therapeutics-q1-gaap-eps-035-misses-026-estimate
AN2 Therapeutics Q1 GAAP EPS $(0.35) Misse...
05/13/2025 22:01:01

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(...

jmp-securities-maintains-market-outperform-on-an2-therapeutics-lowers-price-target-to-2
JMP Securities Maintains Market Outperform...
05/05/2025 13:31:58

JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price t...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/01/2025 21:06:23

an2-therapeutics-reports-phase-3-portion-of-previously-terminated-ebo-301-study-data-outlines-future-milestones-from-boron-chemistry-pipeline
AN2 Therapeutics Reports Phase 3 Portion O...
05/01/2025 20:01:39

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2...

citizens-capital-markets-reiterates-market-outperform-on-an2-therapeutics-maintains-5-price-target
Citizens Capital Markets Reiterates Market...
03/26/2025 13:07:04

Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintai...

an2-therapeutics-q4-2024-gaap-eps-025-beats-026-estimate
AN2 Therapeutics Q4 2024 GAAP EPS $(0.25) ...
03/25/2025 20:06:17

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0....

citizens-capital-markets-reiterates-market-outperform-on-an2-therapeutics-maintains-5-price-target
Citizens Capital Markets Reiterates Market...
02/25/2025 15:32:15

Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintai...

an2-therapeutics-advances-phase-3-ebo-301-trial-wih-pro-based-qol-b-endpoint-setting-stage-for-potential-registrational-pathways
AN2 Therapeutics Advances Phase 3 EBO-301 ...
02/24/2025 12:08:45

AN2 Selects QOL-B as New Phase 3 Primary Efficacy EndpointGoal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potent...

jmp-securities-reiterates-market-outperform-on-an2-therapeutics-maintains-5-price-target
JMP Securities Reiterates Market Outperfor...
02/03/2025 13:56:17

JMP Securities analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 pric...

jmp-securities-reiterates-market-outperform-on-an2-therapeutics-maintains-5-price-target
JMP Securities Reiterates Market Outperfor...
11/19/2024 17:35:00

JMP Securities analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 pric...

td-cowen-downgrades-an2-therapeutics-to-hold
TD Cowen Downgrades AN2 Therapeutics to Hold
11/18/2024 13:55:07

TD Cowen analyst Ritu Baral downgrades AN2 Therapeutics (NASDAQ:ANTX) from Buy to Hold.

an2-therapeutics-provides-important-ebo-301-update-and-highlights-progress-across-boron-chemistry-pipeline-achieved-50-reduction-in-expenditures-through-strategic-realignment-of-operations
AN2 Therapeutics Provides Important EBO-30...
11/13/2024 21:02:32

Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statis...

an2-therapeutics-q3-eps-043-beats-054-estimate
AN2 Therapeutics Q3 EPS $(0.43) Beats $(0....
11/13/2024 21:01:58

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0....

an2-therapeutics-receives-continuation-grant-from-bill--melinda-gates-foundation-to-discover-discover-boron-based-therapies-for-tuberculosis-and-malaria
AN2 Therapeutics Receives Continuation Gra...
10/17/2024 11:03:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION